Nanotherapeutics for Alzheimer’s disease (AD): Past, present and future
- 25 October 2011
- journal article
- review article
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 20 (2) , 97-113
Abstract
Drug delivery to the brain still remains highly challenging for the treatment of Alzheimer’s disease (AD). The development of new practical treatment modalities for the treatment of AD is currently a highly active area of research. Our lack of success in the development of effective therapies for AD is attributed to, but not limited to a number of factors including the complexity of the brain. Besides this, it is recognized that AD is multisystemic in nature and this presents numerous difficulties for the potential treatment of these disorders. Another important reason for the lack of development of effective drugs and drug delivery system for AD is inability to deliver drugs effectively to the brain due to the numerous protective barriers surrounding the CNS i.e. blood-brain barrier (BBB), blood-cerebrospinal fluid barrier (BCSFB) and circumventricular organs (CVOs). Solutions to these problems require enhanced novel research activities that can address each of these problems. This review article provides a concise movement into the current and future applications of nanoparticulate drug delivery systems for the treatment of AD and explores the application of nanotechnology in clinical neuroscience to develop innovative therapeutic modalities for the AD.Keywords
This publication has 165 references indexed in Scilit:
- Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathologyJournal of Controlled Release, 2011
- Apolipoprotein E LDL receptor-binding domain-containing high-density lipoprotein: A nanovehicle to transport curcumin, an antioxidant and anti-amyloid bioflavonoidBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- RETRACTED: Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivoBiochemical Pharmacology, 2010
- Protective actions of sex steroid hormones in Alzheimer’s diseaseFrontiers in Neuroendocrinology, 2009
- Nanoparticle–chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer diseaseNeuroscience Letters, 2009
- Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseasesThe International Journal of Biochemistry & Cell Biology, 2009
- Iron: The Redox-active Center of Oxidative Stress in Alzheimer DiseaseNeurochemical Research, 2007
- Curcumin: The story so farEuropean Journal of Cancer, 2005
- Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting β-amyloid in Alzheimer's diseaseNeuroscience Letters, 2003
- The Role of Iron in Beta Amyloid ToxicityBiochemical and Biophysical Research Communications, 1995